Featured Video
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
15:31 MIN
- CIDP
Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP
Our Experts
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
Jonathan S. Katz, MD
Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California
- MMN
Jonathan S. Katz, MD, is the Director, Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California.
Hans D. Katzberg, MD, MSc, FRCP(C)
University Health Network /Toronto General Hospital Canada
Hans D. Katzberg, MD, MSc, FRCP(C)
University Health Network /Toronto General Hospital Canada
- MMN
Dr. Hans Katzberg is a neuromuscular specialist and clinical investigator at the University Health Network / Toronto General Hospital and has been on faculty at the University of Toronto as Assistant Professor of Neurology.
Carol L. Koski, MD
GBS/CIDP Foundation International
Carol L. Koski, MD
GBS/CIDP Foundation International
- CIDP
- GBS
Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
Michael Lunn, PhD
National Hospital for Neurology and Neurosurgery, Queen Square, London
- CIDP
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.
Back to Top